The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Grow Between 2026 And 2030?
The urine tumor deoxyribonucleic acid (DNA) testing market size has experienced rapid expansion in recent years. This market is projected to expand from $1.18 billion in 2025 to reach $1.36 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. Historically, this growth can be attributed to factors including the increasing incidence of urinary cancers, the adoption of pcr-based urine testing, advancements in sequencing technologies, growing awareness of early cancer detection, and the expansion of hospital diagnostic facilities.
The urine tumor deoxyribonucleic acid (DNA) testing market size is anticipated to experience significant expansion in the upcoming years. It is expected to reach $2.36 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. This projected growth in the forecast period stems from factors such as ai-driven urine dna analysis, development of multiplex and high-throughput assays, expansion of personalized medicine, integration with electronic health records, and the increasing demand for non-invasive monitoring solutions. Furthermore, major trends identified for the forecast period include non-invasive cancer monitoring, liquid biopsy advancements, ai-powered genetic analysis, high-sensitivity urine dna detection, and integration with clinical decision support systems.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Demand?
The rising occurrence of urological cancers is anticipated to fuel the expansion of the urine tumor deoxyribonucleic acid (DNA) testing market in the foreseeable future. These cancers impact the urinary system and male reproductive organs, such as the kidneys, bladder, prostate, and testes. Their frequency is primarily increasing due to aging demographics, given that the likelihood of developing cancer grows with age. Urine tumor DNA testing aids in managing urological cancers through its ability to non-invasively identify cancer-specific genetic mutations present in urine, thereby assisting with early detection, ongoing disease surveillance, and tailored treatment strategies. As an illustration, in December 2025, Cancer Australia, an Australian government department, reported an estimated 28,868 new prostate cancer diagnoses, which constituted approximately 30% of all new cancer cases identified in men. Consequently, the growing incidence of urological cancers is projected to propel the development of the urine tumor deoxyribonucleic acid (DNA) testing market.
How Is Segmentation Applied In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Segment Analysis?
The urine tumor deoxyribonucleic acid (DNA) testing market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction-based, Next-Generation Sequencing, Other technologies
2) By Product Type: Assay Kits, Instruments, Services
3) By Cancer Type: Bladder Cancer, Prostate Cancer, Kidney Cancer, Other Cancer Types
4) By Sample Type: First-Morning Urine, Random Urine Samples, Catheterized Urine Samples
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction
2) By Next Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing
3) By Other Technologies: Microarray Based Testing, Hybridization Based Assays, Mass Spectrometry Based Analysis, Fluorescence In Situ Hybridization
What Trends Are Influencing The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
Leading companies active in the urine tumor deoxyribonucleic acid (DNA) testing market are increasingly dedicated to crafting advanced solutions, such as urine-based liquid biopsy platforms, to enable non-invasive cancer detection, improve diagnostic accuracy, and support personalized treatment planning. Urine-based liquid biopsy platforms are non-invasive diagnostic systems specifically designed to identify and analyze tumor-derived DNA and other biomarkers from urine samples for cancer detection, monitoring, and assessing disease progression. For instance, in September 2024, PreAnalytiX, a joint venture between QIAGEN, a Netherlands-based sample-to-insight provider, and Becton, Dickinson and Company, a US-based medical technology firm, introduced a novel urine-based liquid biopsy solution intended to facilitate high-quality DNA stabilization and extraction for subsequent molecular analyses. Developed to cater to both clinical and research applications, this platform offers standardized urine collection, efficient DNA preservation, and compatibility with next-generation sequencing workflows, thereby contributing to early cancer detection, accurate biomarker assessment, and enhanced patient management.
Who Are The Companies Participating In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Environment?
Major companies operating in the urine tumor deoxyribonucleic acid (DNA) testing market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Illumina Inc., QIAGEN N.V., Bio-Techne Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., MDxHealth SA, Biodesix Inc., Sysmex Inostics GmbH, Pacific Edge Limited, Apostle Inc., Lucence Diagnostics, Pangea Laboratory, Nucleix Ltd, Genomica Lab, Vesica Health, Biocept Inc., Promis Diagnostics Inc.
Get The Full Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report:
Which Region Is The Largest In The Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market?
North America was the largest region in the urine tumor deoxyribonucleic acid (DNA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urine tumor deoxyribonucleic acid (DNA) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Urine Tumor Deoxyribonucleic Acid (DNA) Testing Market 2026, By The Business Research Company
pruritus therapeutic market report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
genomic urine testing market report 2026
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
ocular genetic diagnostic market report 2026
https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model